These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30146916)

  • 41. Association between increased serum osteoprotegerin levels and improvement in bone mineral density after parathyroidectomy in hemodialysis patients.
    Zheng CM; Chu P; Wu CC; Ma WY; Hung KC; Hsu YH; Lin YF; Diang LK; Lu KC
    Tohoku J Exp Med; 2012 Jan; 226(1):19-27. PubMed ID: 22156488
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum osteoprotegerin and sex steroid levels in patients with prostate cancer.
    Varsavsky M; Reyes-Garcia R; Avilés Perez MD; Gonzalez Ramírez AR; Mijan JL; Muñoz-Torres M
    J Androl; 2012; 33(4):594-600. PubMed ID: 21903971
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bone histomorphometry of ovariectomized or orchiectomized rats fed a moderately magnesium-deficient fructose diet and treated with exogenous oestrogen or testosterone.
    Koh ET; Yeh JK; Bourdeau JE; Chen MM; Om AS
    Magnes Res; 1996 Mar; 9(1):13-21. PubMed ID: 8819090
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Osteoprotegerin is an effective countermeasure for spaceflight-induced bone loss in mice.
    Lloyd SA; Morony SE; Ferguson VL; Simske SJ; Stodieck LS; Warmington KS; Livingston EW; Lacey DL; Kostenuik PJ; Bateman TA
    Bone; 2015 Dec; 81():562-572. PubMed ID: 26318907
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Testosterone regulates bone response to inflammation.
    Steffens JP; Herrera BS; Coimbra LS; Stephens DN; Rossa C; Spolidorio LC; Kantarci A; Van Dyke TE
    Horm Metab Res; 2014 Mar; 46(3):193-200. PubMed ID: 24526374
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of osteoporosis using a selective androgen receptor modulator ostarine in an orchiectomized rat model.
    Böker KO; Komrakova M; Fahrendorff L; Spelsberg BR; Hoffmann DB; Schilling AF; Lehmann W; Taudien S; Sehmisch S
    Endocrine; 2023 Sep; 81(3):579-591. PubMed ID: 37378829
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative effects of bicalutamide (Casodex) versus orchidectomy on bone mineral density, bone remodelling, and bone biomechanics in healthy rats.
    Lefort M; Díaz Curiel M; Carrascal MT; Méndez-Dávila C; de la Piedra C
    Urol Int; 2005; 74(4):301-7. PubMed ID: 15897693
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis.
    Franck H; Meurer T; Hofbauer LC
    J Rheumatol; 2004 Nov; 31(11):2236-41. PubMed ID: 15517638
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of testosterone itself and in combination with letrozole on bone mineral density in male rats.
    Saki F; Kasaee SR; Sadeghian F; Talezadeh P; Ranjbar Omrani GH
    J Bone Miner Metab; 2019 Jul; 37(4):668-675. PubMed ID: 30392074
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Soy affects trabecular microarchitecture and favorably alters select bone-specific gene expressions in a male rat model of osteoporosis.
    Soung DY; Devareddy L; Khalil DA; Hooshmand S; Patade A; Lucas EA; Arjmandi BH
    Calcif Tissue Int; 2006 Jun; 78(6):385-91. PubMed ID: 16830200
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
    Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats.
    Vanderschueren D; van Herck E; Nijs J; Ederveen AG; De Coster R; Bouillon R
    Endocrinology; 1997 Jun; 138(6):2301-7. PubMed ID: 9165015
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
    Shaarawy M; Fathy SA; Mehany NL; Hindy OW
    Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis.
    Saidenberg-Kermanac'h N; Corrado A; Lemeiter D; deVernejoul MC; Boissier MC; Cohen-Solal ME
    Bone; 2004 Nov; 35(5):1200-7. PubMed ID: 15542046
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasma osteoprotegerin is associated with testosterone levels but unaffected by pioglitazone treatment in patients with polycystic ovary syndrome.
    Glintborg D; Hermann AP; Rasmussen LM; Andersen M
    J Endocrinol Invest; 2013; 36(7):460-5. PubMed ID: 23211475
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The roles of sclerostin and irisin on bone and muscle of orchiectomized rats.
    Zhou BN; Zhang Q; Lin XY; Hu J; Zhao DC; Jiang Y; Xing XP; Li M
    BMC Musculoskelet Disord; 2022 Dec; 23(1):1049. PubMed ID: 36456918
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
    Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
    Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of risedronate in a rat model of osteopenia due to orchidectomy and disuse: densitometric, histomorphometric and microtomographic studies.
    Libouban H; Blouin S; Moreau MF; Baslé MF; Audran M; Chappard D
    Micron; 2008 Oct; 39(7):998-1007. PubMed ID: 18023586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.